News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Syneron Medical Ltd. (ELOS) to Present at the 11th Annual JMP Securities Research Conference


5/4/2012 10:57:15 AM

YOKNEAM, ISRAEL--(Marketwire - May 03, 2012) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that Louis P. Scafuri, Chief Executive Officer, is scheduled to present at the 11th Annual JMP Securities Research Conference in San Francisco, CA.

Conference: 11th Annual JMP Securities Research Conference
Date: Wednesday, May 16, 2012
Time: 9:00 a.m. PT / 12:00 p.m. ET

The presentation will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at www.syneron.com. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation.

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.


Contacts:

Asaf Alperovitz
Chief Financial Officer
+ 972 73 244 2283
Email: Email Contact

Zack Kubow
The Ruth Group
646-536-7020
Email: Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES